MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners' RDT platform in development in partnership with Orano Med Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profile First-in-human study in planning with initial data expected in 2025 RDT platform expanding with portfolio of additional targets under evaluation About Orano Med SAS "Three years ago, we started our venture into the radiotherapy space. We have made tremendous progress ...

"The Phase 1 data for MP0317 demonstrate the ability of the FAP x CD40 DARPin to avoid the systemic toxicities of CD40 agonists while showcasing truly promising modulation of the tumor microenvironment," said Philippe Legenne, MD, MBA, Molecular Partners' acting Chief Medical Officer. "This further deepens the clinical evidence supporting DARPins' ability to deliver multi-specific candidates with enhanced capabilities in oncology including localized activation of powerful immunostimulatory molecules. We wil ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first quarter of 2024. "This quarter we demonstrated ...

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in combination with azacitidine/venetoclaxOngoing Phase 1/ ...

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States. "We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel," said Nadine Zahnd, Ma ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS conso ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Patrick Amstutz Patrick Amstutz Molecular Partners AG (NASDAQ:MOLN) Q2 2023 Earnings Conference Call August 25, 2023 8:00 AM ET Seth Lewis - SVP, IR Patrick Amstutz - CEO Robert Hendriks - SVP, Finance Daina Graybosch - SVB Leerink LLC Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Good day, and welcome to the Molecular Partners First Half 2023 Results Conference Call. [Operator Instructions] Thank you. Seth Lewis, Senior Vice President of Investor Relations you may begin your conference. Thanks R ...

Exhibit 99.1 Condensed consolidated interim financial statements (unaudited) | | | March 31, | December | | --- | --- | --- | --- | | Condensed consolidated interim statement of financial position as of | | 2023 | 31, 2022 | | in CHF thousands | Note | | | | Assets | | | | | Property, plant and equipment | | 6,768 | 7,235 | | Intangible assets | | 287 | 271 | | Total non-current assets | | 7,055 | 7,506 | | Short-term time deposits | | 158,442 | 161,198 | | Other current assets | | 3,363 | 4,589 | | Trade a ...

Financial Data and Key Metrics Changes - The company reported revenue of approximately CHF 190 million for 2022, primarily driven by collaborations with Novartis, with CHF 173 million attributed to this partnership [70][59] - Operating expenses were reported at CHF 73 million, aligning with previous guidance of 70% to 75% [59] - The company ended the year with a cash balance of nearly CHF 250 million, which is expected to sustain operations into 2026 [18][36] Business Line Data and Key Metrics Changes - The company is focusing on its tri-specific T-cell engager, 533, in acute myeloid leukemia (AML), with initial patient dosing completed and ongoing preclinical data supporting its efficacy [67][60] - The local CD40 agonist, MPO317, has successfully reached the highest dose in its trial without dose-limiting toxicities, indicating a promising mode of action [60][67] Market Data and Key Metrics Changes - The company is exploring partnerships for its Radio DARPin therapy platform, which aims to expand the ligand space and target a broader range of tumors [16][20] - The collaboration with Novartis includes two exclusive targets, with potential for additional partnerships to enhance access to radioisotopes [16][20] Company Strategy and Development Direction - The company emphasizes differentiation through its DARPin technology, aiming to address unmet medical needs and generate early clinical readouts [55][14] - The strategy includes potential partnerships to advance products that may not be best developed in-house, focusing on generating patient value [55][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position, highlighting the ability to fund operations through 2026 without relying on immediate partnerships [10][36] - The company is optimistic about the potential of its pipeline, particularly the 533 program, and aims to provide initial safety and efficacy results in the second half of the year [60][38] Other Important Information - The company is committed to corporate sustainability and ESG principles, integrating these values into its culture and operations [35][17] - The company is actively working on reducing kidney uptake in its therapies, which is a common challenge for protein-based treatments [4][6] Q&A Session Summary Question: What are the plans for expanding clinical sites for 533? - The initial trials for 533 are planned in Europe, with intentions to expand to the U.S. contingent on positive results [29][25] Question: What is the status of the Novartis collaboration regarding kidney accumulation issues? - The company clarified that kidney accumulation is a systemic issue for protein therapeutics and is not a rate-limiting factor for the collaboration with Novartis [23][22] Question: What are the potential partnerships for the MPO317 program? - Likely partners include companies in immuno-oncology that have a vested interest in CD40 and FAP combinations, especially in light of competitive data from Roche [82][81]